BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $140,892 | -9.9% | 19,900 | -10.4% | 0.01% | -9.1% |
| Q2 2023 | $156,288 | -15.6% | 22,200 | 0.0% | 0.01% | -15.4% |
| Q1 2023 | $185,148 | -27.4% | 22,200 | 0.0% | 0.01% | -35.0% |
| Q4 2022 | $254,856 | -9.0% | 22,200 | 0.0% | 0.02% | -13.0% |
| Q3 2022 | $280,000 | +18.6% | 22,200 | -0.4% | 0.02% | +21.1% |
| Q2 2022 | $236,000 | -52.9% | 22,300 | -27.6% | 0.02% | -44.1% |
| Q1 2022 | $501,000 | -1.8% | 30,800 | -16.3% | 0.03% | +3.0% |
| Q4 2021 | $510,000 | -6.8% | 36,800 | +2.0% | 0.03% | -15.4% |
| Q3 2021 | $547,000 | +69.3% | 36,065 | +76.8% | 0.04% | +56.0% |
| Q2 2021 | $323,000 | +41.7% | 20,400 | -8.9% | 0.02% | +13.6% |
| Q1 2021 | $228,000 | +36.5% | 22,400 | 0.0% | 0.02% | +29.4% |
| Q4 2020 | $167,000 | – | 22,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |